We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease (“CD”). For the CD indication, Tremfya has gained approval for both subcutaneous (“SC”) and intravenous (“IV”) induction options.
The approval for the CD indication was based on data from the phase III GALAXI and GRAVITI studies, which demonstrated the robust efficacy of SC or IV Tremfya in achieving clinical and endoscopic endpoints.
So far this year, J&J’s shares have risen 12.7% compared with the industry’s 7.0% increase.
Image Source: Zacks Investment Research
JNJ’s Tremfya in IBD Conditions
Tremfya was approved for its first IBD condition, moderately to severely active ulcerative colitis (“UC”), in September 2024. Tremfya, an IL-23 inhibitor, is already approved to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in several countries, including the United States and the EU. Crohn’s disease marks the fourth indication for Tremfya in the United States. Tremfya is under review in the EU for both UC and CD indications.
Tremfya is a Key Top-Line Driver for JNJ
Tremfya is an important drug in J&J’s immunology drug portfolio and a key driver of top-line growth. The drug generated sales of $3.67 billion in 2024, up 16.6% year over year, driven by strong market growth and share gains.
The approval of Tremfya for the IBD conditions, UC and CD is the key to its growth. J&J expects Tremfya to be a $5 billion product with approvals in IBD conditions.
Competition in the IBD Space
In recent years, there has been a surge in the prevalence of gastrointestinal disorders like UC and CD due to genetic factors, environmental factors and lifestyle changes. In addition, immune system irregularities, higher diagnosis rates, increased focus on early diagnosis and favorable reimbursement policies in developed countries are driving demand for IBD treatments.
Several big drugmakers are developing new medicines with novel mechanisms of action to help patients with UC and CD achieve long-term clinical remission. Some other key players in the IBD market are AbbVie (ABBV - Free Report) , Eli Lilly (LLY - Free Report) , Pfizer, Novartis, Merck (MRK - Free Report) , Sanofi, Gilead and Amgen. Some of these companies have also in-licensed rights to IBD candidates with improved clinical profiles from smaller drugmakers in the past two to three years.
AbbVie has been seeing strong performance of its key immunology drugs, Skyrizi and Rinvoq, in IBD indications. In 2024, AbbVie acquired smaller biotechs like Landos Biopharma and Celsius Therapeutics, which are making novel drugs for treating IBD. It also signed a license agreement with China’s FutureGen to develop a next-generation anti-TL1A antibody for IBD.
Lilly’s Omvoh was approved for UC in the United States, Europe and Japan in 2023. Omvoh was approved for CD in the United States in January 2025, while applications are under review in Europe and Japan. In 2024, Lilly acquired small biotech Morphic Therapeutics, whose lead pipeline candidate is MORF-057, in mid-stage development for both UC and CD.
In 2023, Merck acquired small biotech Prometheus Biosciences, which added tulisokibart to its pipeline. Tulisokibart, a novel TL1A inhibitor, is being developed in phase III for UC.
In 2023, Roche acquired Telavant, including rights to the novel TL1A-directed antibody (RVT-3101) from Roivant for the treatment of IBD conditions.
In October 2023, Sanofiin-licensed rights to jointly develop and commercialize Teva Pharmaceutical’s IBD candidate, duvakitug/TEV-48574, an anti-TL1A therapy. Duvakitug is being evaluated in a phase IIb study for UC and CD, with a phase III study expected to begin this year.
Image: Bigstock
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
Johnson & Johnson (JNJ - Free Report) announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease (“CD”). For the CD indication, Tremfya has gained approval for both subcutaneous (“SC”) and intravenous (“IV”) induction options.
The approval for the CD indication was based on data from the phase III GALAXI and GRAVITI studies, which demonstrated the robust efficacy of SC or IV Tremfya in achieving clinical and endoscopic endpoints.
So far this year, J&J’s shares have risen 12.7% compared with the industry’s 7.0% increase.
Image Source: Zacks Investment Research
JNJ’s Tremfya in IBD Conditions
Tremfya was approved for its first IBD condition, moderately to severely active ulcerative colitis (“UC”), in September 2024. Tremfya, an IL-23 inhibitor, is already approved to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in several countries, including the United States and the EU. Crohn’s disease marks the fourth indication for Tremfya in the United States. Tremfya is under review in the EU for both UC and CD indications.
Tremfya is a Key Top-Line Driver for JNJ
Tremfya is an important drug in J&J’s immunology drug portfolio and a key driver of top-line growth. The drug generated sales of $3.67 billion in 2024, up 16.6% year over year, driven by strong market growth and share gains.
The approval of Tremfya for the IBD conditions, UC and CD is the key to its growth. J&J expects Tremfya to be a $5 billion product with approvals in IBD conditions.
Competition in the IBD Space
In recent years, there has been a surge in the prevalence of gastrointestinal disorders like UC and CD due to genetic factors, environmental factors and lifestyle changes. In addition, immune system irregularities, higher diagnosis rates, increased focus on early diagnosis and favorable reimbursement policies in developed countries are driving demand for IBD treatments.
Several big drugmakers are developing new medicines with novel mechanisms of action to help patients with UC and CD achieve long-term clinical remission. Some other key players in the IBD market are AbbVie (ABBV - Free Report) , Eli Lilly (LLY - Free Report) , Pfizer, Novartis, Merck (MRK - Free Report) , Sanofi, Gilead and Amgen. Some of these companies have also in-licensed rights to IBD candidates with improved clinical profiles from smaller drugmakers in the past two to three years.
AbbVie has been seeing strong performance of its key immunology drugs, Skyrizi and Rinvoq, in IBD indications. In 2024, AbbVie acquired smaller biotechs like Landos Biopharma and Celsius Therapeutics, which are making novel drugs for treating IBD. It also signed a license agreement with China’s FutureGen to develop a next-generation anti-TL1A antibody for IBD.
Lilly’s Omvoh was approved for UC in the United States, Europe and Japan in 2023. Omvoh was approved for CD in the United States in January 2025, while applications are under review in Europe and Japan. In 2024, Lilly acquired small biotech Morphic Therapeutics, whose lead pipeline candidate is MORF-057, in mid-stage development for both UC and CD.
In 2023, Merck acquired small biotech Prometheus Biosciences, which added tulisokibart to its pipeline. Tulisokibart, a novel TL1A inhibitor, is being developed in phase III for UC.
In 2023, Roche acquired Telavant, including rights to the novel TL1A-directed antibody (RVT-3101) from Roivant for the treatment of IBD conditions.
In October 2023, Sanofiin-licensed rights to jointly develop and commercialize Teva Pharmaceutical’s IBD candidate, duvakitug/TEV-48574, an anti-TL1A therapy. Duvakitug is being evaluated in a phase IIb study for UC and CD, with a phase III study expected to begin this year.
J&J’s Zacks Rank
J&J currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Johnson & Johnson Price and Consensus
Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote